WAS

Across TCGA pan-cancer cohorts, WAS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated WAS data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher WAS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated WAS expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and COAD are the cancer types where WAS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.685	0.890	.004	13	view →
LSCC	OS	Tertile	III,IV	0.970	0.672	.024	8	view →
COAD	DFS	Quartile	All	0.905	1.000	.047	6	view →
LUAD	DFS	Median	All	0.764	0.527	.010	5	view →
GBM	OS	Quartile	All	0.217	0.545	.027	4	view →
PDAC	DFS	Quartile	III,IV	0.979	0.501	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

WAS–HNSC (DFS)

Open the HNSC breakdown →